Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 261

1.

Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals.

Noguera A, Fortuny C, Muñoz-Almagro C, Sanchez E, Vilaseca MA, Artuch R, Pou J, Jimenez R.

Pediatrics. 2004 Nov;114(5):e598-603. Epub 2004 Oct 18.

PMID:
15492359
2.

Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy.

Alimenti A, Burdge DR, Ogilvie GS, Money DM, Forbes JC.

Pediatr Infect Dis J. 2003 Sep;22(9):782-9.

PMID:
14506368
3.

Serum lactate levels in infants exposed peripartum to antiretroviral agents to prevent mother-to-child transmission of HIV: Agence Nationale de Recherches Sur le SIDA et les Hépatites Virales 1209 study, Abidjan, Ivory Coast.

Ekouevi DK, Touré R, Becquet R, Viho I, Sakarovitch C, Rouet F, Towne-Gold B, Fassinou P, Leroy V, Blanche S, Dabis F; Agence Nationale de Recherches Sur le SIDA 1201/1202 Ditrame Plus Study Group.

Pediatrics. 2006 Oct;118(4):e1071-7. Epub 2006 Sep 1.

4.

Hematologic effects of maternal antiretroviral therapy and transmission prophylaxis in HIV-1-exposed uninfected newborn infants.

Feiterna-Sperling C, Weizsaecker K, Bührer C, Casteleyn S, Loui A, Schmitz T, Wahn V, Obladen M.

J Acquir Immune Defic Syndr. 2007 May 1;45(1):43-51.

PMID:
17356471
5.

Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy.

John M, Moore CB, James IR, Nolan D, Upton RP, McKinnon EJ, Mallal SA.

AIDS. 2001 Apr 13;15(6):717-23.

PMID:
11371686
6.

Hyperlactatemia in human immunodeficiency virus-infected children receiving antiretroviral treatment.

Noguera A, Fortuny C, Sanchez E, Artuch R, Vilaseca MA, Muñoz-Almagro C, Pou J, Jiménez R.

Pediatr Infect Dis J. 2003 Sep;22(9):778-82.

PMID:
14506367
7.

Growth of human immunodeficiency virus-uninfected children exposed to perinatal zidovudine for the prevention of mother-to-child human immunodeficiency virus transmission.

Briand N, Le Coeur S, Traisathit P, Karnchanamayul V, Hansudewechakul R, Ngampiyasakul C, Bhakeecheep S, Ithisukanan J, Hongsiriwon S, McIntosh K, Lallemant M.

Pediatr Infect Dis J. 2006 Apr;25(4):325-32.

PMID:
16567984
8.

Hyperlactatemia and in utero exposure to antiretrovirals: is the control group the clue?

Soler-Palacín P, Martín-Nalda A, Martínez-Gómez X, Melendo S, Riudor E, Arranz JA, Espiau M, Figueras C.

AIDS Res Hum Retroviruses. 2012 Aug;28(8):752-8. doi: 10.1089/AID.2011.0198. Epub 2011 Nov 16.

PMID:
22010980
9.

Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort.

Barret B, Tardieu M, Rustin P, Lacroix C, Chabrol B, Desguerre I, Dollfus C, Mayaux MJ, Blanche S; French Perinatal Cohort Study Group.

AIDS. 2003 Aug 15;17(12):1769-85.

PMID:
12891063
10.

In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children.

Brogly SB, Ylitalo N, Mofenson LM, Oleske J, Van Dyke R, Crain MJ, Abzug MJ, Brady M, Jean-Philippe P, Hughes MD, Seage GR 3rd.

AIDS. 2007 May 11;21(8):929-38.

PMID:
17457086
11.
12.

Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study.

Boubaker K, Flepp M, Sudre P, Furrer H, Haensel A, Hirschel B, Boggian K, Chave JP, Bernasconi E, Egger M, Opravil M, Rickenbach M, Francioli P, Telenti A.

Clin Infect Dis. 2001 Dec 1;33(11):1931-7. Epub 2001 Oct 23.

PMID:
11692306
13.

Mitochondrial disease in the offspring as a result of antiretroviral therapy.

Venhoff N, Walker UA.

Expert Opin Drug Saf. 2006 May;5(3):373-81. Review.

PMID:
16610967
14.

A prospective controlled study of neurodevelopment in HIV-uninfected children exposed to combination antiretroviral drugs in pregnancy.

Alimenti A, Forbes JC, Oberlander TF, Money DM, Grunau RE, Papsdorf MP, Maan E, Cole LJ, Burdge DR.

Pediatrics. 2006 Oct;118(4):e1139-45. Epub 2006 Aug 28.

PMID:
16940166
15.

Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers.

Poirier MC, Divi RL, Al-Harthi L, Olivero OA, Nguyen V, Walker B, Landay AL, Walker VE, Charurat M, Blattner WA; Women and Infants Transmission Study (WITS) Group.

J Acquir Immune Defic Syndr. 2003 Jun 1;33(2):175-83.

PMID:
12794551
16.

Morbidity and mortality during the first two years of life among uninfected children born to human immunodeficiency virus type 1-infected women: the women and infants transmission study.

Paul ME, Chantry CJ, Read JS, Frederick MM, Lu M, Pitt J, Turpin DB, Cooper ER, Handelsman EL.

Pediatr Infect Dis J. 2005 Jan;24(1):46-56.

PMID:
15665710
17.

Maternal antiretrovirals and hepatic enzyme, hematologic abnormalities among human immunodeficiency virus type 1-uninfected infants: the NISDI perinatal study.

Mussi-Pinhata MM, Rego MA, Freimanis L, Kakehasi FM, Machado DM, Cardoso EM, Read JS; NISDI Perinatal Protocol Study Group.

Pediatr Infect Dis J. 2007 Nov;26(11):1032-7.

PMID:
17984811
18.

Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.

Kovacs A, Cowles MK, Britto P, Capparelli E, Fowler MG, Moye J, McIntosh K, Rathore MH, Pitt J, Husson RN.

Pediatr Infect Dis J. 2005 Jun;24(6):503-9.

PMID:
15933559
19.

Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy.

Shiramizu B, Shikuma KM, Kamemoto L, Gerschenson M, Erdem G, Pinti M, Cossarizza A, Shikuma C.

J Acquir Immune Defic Syndr. 2003 Apr 1;32(4):370-4.

PMID:
12640193
20.

Zidovudine administration during pregnancy and mitochondrial disease in the offspring.

Tovo PA, Chiapello N, Gabiano C, Zeviani M, Spada M.

Antivir Ther. 2005;10(6):697-9.

PMID:
16218167

Supplemental Content

Support Center